Tan J S, Wishnow R M, Talan D A, Duncanson F P, Norden C W
Northeastern Ohio University College of Medicine, Akron 44304.
Antimicrob Agents Chemother. 1993 Aug;37(8):1580-6. doi: 10.1128/AAC.37.8.1580.
We compared the efficacy and safety of two beta-lactam-beta-lactamase inhibitor combinations, namely, piperacillin-tazobactam and ticarcillin-clavulanate, in the treatment of complicated bacterial infections of skin that required hospitalization. The study was a randomized, double-blind, comparative trial involving 20 centers. The infections were classified as (i) cellulitis with drainage, (ii) cutaneous abscess, (iii) diabetic or ischemic foot infection, and (iv) infected wounds and ulcers with drainage. The clinical response rates were comparable for the two treatment regimens (61% of the patients were cured with piperacillin-tazobactam and ticarcillin-clavulanate and improvement was seen in 15 and 16% of patients treated with piperacillin-tazobactam and ticarcillin-clavulanate, respectively). Both regimens were found to be safe and well tolerated. These data support the use of piperacillin-tazobactam for initial empiric therapy of hospitalized patients with complicated skin and skin structure infections.
我们比较了两种β-内酰胺类-β-内酰胺酶抑制剂组合（即哌拉西林-他唑巴坦和替卡西林-克拉维酸）在治疗需要住院的复杂皮肤细菌感染中的疗效和安全性。该研究是一项涉及20个中心的随机、双盲、对照试验。感染分为以下几类：（i）伴有引流的蜂窝织炎，（ii）皮肤脓肿，（iii）糖尿病或缺血性足部感染，以及（iv）伴有引流的感染伤口和溃疡。两种治疗方案的临床有效率相当（哌拉西林-他唑巴坦治疗的患者中61%治愈，替卡西林-克拉维酸治疗的患者中分别有15%和16%病情改善）。两种方案均被证明是安全且耐受性良好的。这些数据支持哌拉西林-他唑巴坦用于住院的复杂皮肤及皮肤结构感染患者的初始经验性治疗。
